2012 Volume 34 Issue 6 Pages 435-439
Among 44 patients who started the administration of dabigatran etexilate, we found 6 patients whose active partial thromboplastin time (APTT) were prolonged over 70 seconds, and 3 patients with hemorrhagic complications (2 patients; macrohematuria, 1 patient; subcutaneous hematoma). APTT was significantly prolonged by the administration of dabigatran etexilate. We must notice that the extreme prolongation of APTT may occur for such as senile patients with renal dysfunction. And we will recommend the measurement of APTT at the first phase after the starting of dabigatran etexilate.